Effect of recombinant SP-C surfactant in a porcine lavage model of acute lung injury

Journal of Applied Physiology

Volumn 88, Issue 2, 2000, Pages 674-681

  Spragg, R G ^a,d   Smith, R M ^a   Harris, K ^a   Lewis, J ^b   Hafner D ^c   Germann, P ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c ALTANA PHARMA AG   (Germany)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute respiratory distress syndrome; Phospholipids; Pulmonary surfactant; Surfactant apoprotein C

Indexed keywords

SURFACTANT PROTEIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG EFFECT; GAS EXCHANGE; LUNG INJURY; LUNG LAVAGE; NONHUMAN; OXYGEN TENSION; PRIORITY JOURNAL; SWINE;

EID: 0033960857     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/jappl.2000.88.2.674     Document Type: Article

References (30)

1. Alvarez, F. J., L. F. Alfonso, E. Gastiasoro, J. Lopez-Heredia, A. Arnaiz, and A. Valls-i-Soler. The effects of multiple small doses of exogenous surfactant on experimental respiratory failure induced by lung lavage in rats. Acta Anaesthesiol. Scand. 39: 970-974, 1995.
2. Anzueto, A., R. Baughman, K. K. Guntupalli, J. G. Weg, H. P. Wiedemann, A. A. Raventos, F. Lemaire, W. Long, D. S. Zaccardelli, and E. N. Pattishall. Aerosolized surfactants in adults with sepsis-induced acute respiratory distress syndrome. N. Engl. J. Med. 334: 1417-1421, 1996.
3. Berggren, P., B. Lachmann, T. Curstedt, G. Grossmann, and B. Robertson. Gas exchange and lung morphology after surfactant replacement in experimental adult respiratory distress syndrome induced by repeated lung lavage. Acta Anaesthesiol. Scand. 30: 321-328, 1986.
4. Curstedt, T., H. Jornvall, B. Robertson, T. Bergman, and P. Berggren. Two hydrophobic low-molecular-mass protein fractions of pulmonary surfactant. Characterization and biophysical activity. Eur. J. Biochem. 168: 255-262, 1987.
5. Davis, A. J., A. H. Jobe, D. Hafner, and M. Ikegami. Lung function in premature lambs and rabbits treated with a recombinant SP-C surfactant. Am. J. Respir. Crit. Care Med. 157: 553-559, 1998.
6. Enhorning, G. A pulsating bubble technique for evaluating pulmonary surfactant. J. Appl. Physiol. 43: 198-201, 1977.
7. Gilliard, N., P. M. Richman, T. A. Merritt, and R. G. Spragg. Effect of volume and dose on the pulmonary distribution of exogenous surfactant administered to normal rabbits or to rabbits with oleic acid lung injury. Am. Rev. Respir. Dis. 141: 743-747, 1990.
8. Glasser, S. W., T. R. Korfhagen, C. M. Perme, T. J. Pilot-Matias, S. E. Kister, and J. A. Whitsett. Two SP-C genes encoding human pulmonary surfactant proteolipid. J. Biol. Chem. 263: 10326-10331, 1988.
9. Gregory, T. J., W. J. Longmore, M. A. Moxley, J. A. Whitsett, C. R. Reed, A. A. I. Fowler, L. D. Hudson, R. J. Maunder, C. Crim, and T. M. Hyers. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J. Clin. Invest. 88: 1976-1981, 1991.
10. Gregory, T. J., K. P. Steinberg, R. Spragg, J. E. Gadek, T. M. Hyers, W. J. Longmore, M. A. Moxley, G. Z. Cai, R. D. Hite, R. M. Smith, L. D. Hudson, C. Crim, P. Newton, B. R. Mitchell, and A. J. Gold. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 155: 1309-1315, 1997.
11. Hafner, D., R. Beume, U. Kilian, G. Krasznai, and B. Lachmann. Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS). Br. J. Pharmacol. 115: 451-458, 1995.
12. Hafner, D., P. G. Germann, and D. Hauschke. Effects of lung surfactant factor (LSF) treatment on gas exchange and histopathological changes in an animal model of adult respiratory distress syndrome (ARDS): comparison of recombinant LSF with bovine LSF. Pulm. Pharmacol. 7: 319-332, 1994.
13. Hallman, M., R. G. Spragg, J. H. Harrell, K. M. Moser, and L. Gluck. Evidence of lung surfactant abnormality in respiratory failure: study of bronchoalveolar lavage PL, surface activity, phospholipase activity, and plasma myoinositol. J. Clin. Invest. 70: 673-683, 1982.
14. Hawgood, S., A. Ogawa, K. Yukitake, M. Schlueter, C. Brown, T. White, D. Buckley, D. Lesikar, and B. Benson. Lung function in premature rabbits treated with recombinant human surfactant protein-C. Am. J. Respir. Crit. Care Med. 154: 484-490, 1996.
15. Jobe, A. H. Pulmonary surfactant therapy. N. Engl. J. Med. 328: 861-868, 1993.
16. Krause, M., T. Olsson, A. B. Law, R. A. Parker, D. P. Lindstrom, H. W. Sundell, and R. B. Cotton. Effect of volume recruitment on response to surfactant treatment in rabbits with lung injury. Am. J. Respir. Crit. Care Med. 156: 862-866, 1997.
17. Lewis, J., J. Dhillon, R. S. Singh, C. C. Johnson, and T. C. Frewen. Exogenous surfactant therapy for pediatric patients with the acute respiratory distress syndrome. Can. Respir. J. 4: 21-26, 1997.
18. Lewis, J. F., J. Goffin, P. Yue, L. A. McCaig, D. Bjarneson, and R. A. Veldhuizen. Evaluation of exogenous surfactant treatment strategies in an adult model of acute lung injury. J. Appl. Physiol. 80: 1156-1164, 1996.
19. Lewis, J. F., and A. H. Jobe. Surfactant and the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 147: 218-233, 1993.
20. Merritt, T. A., C. G. Cochrane, K. Holcomb, B. Bohl, M. Hallman, D. Strayer, D. K. Edwards, and L. Gluck. Elastase and alpha 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J. Clin. Invest. 72: 656-666, 1983.
21. Ogawa, A., C. L. Brown, M. A. Schlueter, B. J. Benson, J. A. Clements, and S. Hawgood. Lung function, surfactant apoprotein content, and level of PEEP in prematurely delivered rabbits. J. Appl. Physiol. 77: 1840-1849, 1994.
22. Petty, T. L., W. G. Silvers, G. W. Paul, and R. E. Stanford. Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome. Chest 75: 571-574, 1979.
23. Seeger, W., U. Pison, R. Buchhorn, U. Obertacke, and T. Joka. Surfactant abnormalities and adult respiratory failure. Lung 168, Suppl.: 891-902, 1990.
24. Smith, R. M., and R. G. Spragg. Pathology of the surfactant system of the mature lung. Am. J. Respir. Crit. Care Med. 155: 756-760, 1997.
25. Spragg, R. G., N. Gilliard, P. Richman, R. M. Smith, R. D. Hite, D. Pappert, B. Robertson, T. Curstedt, and D. Strayer. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 105: 195-202, 1994.
26. Suzuki, Y., T. Curstedt, G. Grossmann, T. Kobayashi, R. Nilsson, K. Nohara, and B. Robertson. The role of the low molecular weight (less than or equal to 15,000 daltons) apoproteins of pulmonary surfactant. Eur. J. Respir. Dis. 69: 336-345, 1986.
27. Walmrath, D., A. Günther, H. A. Ghofrani, R. Schermuly, T. Schneider, F. Grimminger, and W. Seeger. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am. J. Respir. Crit. Care Med. 154: 57-62, 1996.
28. Warr, R. G., S. Hawgood, D. I. Buckley, T. M. Crisp, J. Schilling, B. J. Benson, P. L. Ballard, J. A. Clements, and R. T. White. Low molecular weight human pulmonary surfactant protein (SP5): isolation, characterization, and cDNA and amino acid sequences. Proc. Natl. Acad. Sci. USA 84: 7915-7919, 1987.
29. Willson, D. F., J. H. Jiao, L. A. Bauman, A. Zaritsky, H. Craft, K. Dockery, D. Conrad, and H. Dalton. Calf's lung surfactant extract in acute hypoxemic respiratory failure in children. Crit. Care Med. 24: 1316-1322, 1996.
30. Yu, S. H., D. Wallace, B. Bhavnani, G. Enhorning, P. G. Harding, and F. Possmayer. Effect of reconstituted pulmonary surfactant containing the 6000-dalton hydrophobic protein on lung compliance of prematurely delivered rabbit fetuses. Pediatr. Res. 23: 23-30, 1988.